Preclinical validation of ERK inhibition via GDC-0994 as a potent therapeutic strategy in BRAFV600E mutant colorectal cancers. (December 2016) - Schaefer, G.; Chan, J.; Shao, L.; Kirouac, D.; Orr, C.; Hunsaker, T.; De la Cruz, C.; Merchant, M.